Picking up post #2: that is the part I would want checked first.
Hepatic steatosis and MASH: a phase 2 trial in semaglutide for steatohepatitis showed resolution was more frequent on treatment. Histological resolution is a surrogate for long-term clinical outcomes like cirrhosis.
Chronic kidney disease: compounds in this class have renal benefit in people with kidney disease. The benefit appears to be additive to other renal-protective agents, not a replacement for them.
I read post #35 twice before replying, because I had assumed the opposite.
Bariatric surgery history: altered anatomy after surgery affects absorption. That matters for oral medications and for reconstituted solutions. Discussing specific medications and doses with a clinician familiar with bariatric surgery is prudent.
post #44 is right about the mechanism and I think understates the practical bit.
Type 2 diabetes: the population with the largest evidence base for these compounds. The SURPASS and SUSTAIN programmes established glycaemic benefit. The renal and cardiovascular benefit evidence is separate from the glycaemic benefit evidence.
Bariatric surgery history: altered anatomy after surgery affects absorption. That matters for oral medications and for reconstituted solutions. Discussing specific medications and doses with a clinician familiar with bariatric surgery is prudent.
Cardiovascular disease: several compounds have cardiovascular outcome trials. SELECT was in people without diabetes; SUSTAIN 6 was in high-risk diabetes. Absolute benefit is largest in high-risk people.
Cardiovascular disease: several compounds have cardiovascular outcome trials. SELECT was in people without diabetes; SUSTAIN 6 was in high-risk diabetes. Absolute benefit is largest in high-risk people.
Read the full topic (90 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Revisiting: Gallbladder disease risk with rapid weight loss
Revisiting: Gallbladder disease risk with rapid weight loss Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…
|
2 | 2k | 9mo | |
|
Cardiovascular risk: reading the outcome trials as a set
Cardiovascular risk: reading the outcome trials as a set Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The published…
|
4 | 12k | 5mo | |
|
Chronic kidney disease and the FLOW result
Posting this under the heading it deserves: Chronic kidney disease and the FLOW result Everything below is what sits behind that. General question, not a request for advice about my own care — I know the…
|
+34 | 38 | 33k | 23mo |
|
PCOS and metabolic overlap: what is and is not studied
On the subject in the title: PCOS and metabolic overlap: what is and is not studied Working notes rather than a conclusion. Asking about a population rather than about a person. The published trials in this…
|
3 | 6.6k | 1d | |
|
Gallbladder disease risk with rapid weight loss
Posting this under the heading it deserves: Gallbladder disease risk with rapid weight loss Everything below is what sits behind that. General question, not a request for advice about my own care — I know the…
|
+56 | 63 | 34k | 18mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Adolescents: a distinct evidence base
Adolescents: a distinct evidence base Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The published trials in this…
|
3 | 11k | 9h | |
|
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold?
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N…
|
+58 | 62 | 49k | 20mo |
|
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since
Posting this under the heading it deserves: Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022)…
|
+125 | 132 | 39k | 16mo |
|
What SELECT changed about how semaglutide is discussed, and what it did not
Asking directly, because I could not find a straight answer: What SELECT changed about how semaglutide is discussed, and what it did not Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
|
+120 | 132 | 2k | 14mo |
|
[2026 update] People with a low starting BMI: where the evidence stops
People with a low starting BMI: where the evidence stops Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The published…
|
+19 | 23 | 62k | 23mo |